756 P. R o b s o n
Ungerleider T, Andrysiak T, Fairbanks L, et al (1982) Cannabis and cancer chemotherapy:
a comparison of oral delta-9-THC and prochlorperazine. Cancer 50:636–645
Vaney C, Jobin P, Tschopp F, Heinzel M, Schnelle M (2002) Efficacy, safety and tolerability of
an orally administered cannabis extract in the treatment of spasticity in patients with
multiple sclerosis. In: Symposium on the Cannabinoids; Asilomar Conference Center,
Pacific Grove, CA: International Cannabinoid Research Society; 13 July 2002, p 57
Venderova K, Ruzicka E, Vorisek V, Visnovsky P (2003) Cannabis and Parkinson’s disease:
subjective improvement of symptoms and levodopa-induced dyskinesias. International
Cannabinoid Research Society 13th Annual Symposium on the Cannabinoids, abstr 145
Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on
anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr
Psychiatry 12:913–919
Wade DT, Robson PJ, House H, et al (2003) A preliminary controlled study to determine
whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Clin Rehabil 17:18–26
WadeDT,MakelaP,RobsonP,etal(2004)Docannabis-basedmedicinalextractshavegeneral
or specific effects on symptoms in multiple sclerosis? A double-blind, randomised,
placebo-controlled study in 160 patients. Mult Scler 10:434–442
Wallace MJ, Blair RE, Falenski KW, et al (2003) The endogenous cannabinoid system regu-
lates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol
Exp Ther 307:129–137
Ware MA, Adams H, Guy G (2003) The medicinal use of cannabis in the United Kingdom.
International Cannabinoid Research Society 13th Annual Symposium on the Cannabi-
noids, abstr 139
Whittle BA, Guy GW, Robson P (2001) Prospects for new cannabis-based prescription
medicines. J Cannabis Ther 1:183–205
Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central
cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143:315–317
Williams SJ, Hartley JPR, Graham JDP (1976) Bronchodilator effect of delta-9-THC admin-
istered by aerosol to asthmatic patients. Thorax 31:720–723
Wisbeck GA, Schuckit MA, Kalmijn JA (1996) An evaluation of the history of a marijuana
withdrawal syndrome in a large population. Addiction 91:1469–1478
Wright K, Rooney N, Tate J, et al (2003) Functional cannabinoid receptor expression in
human colonic epithelium. International Cannabinoid Research Society 13th Annual
Symposium on the Cannabinoids, abstr 25
Young CA, Rog DJ (2003) Randomised controlled trial of cannabis based medicinal extracts
(CBME) in central neuropathic pain due to multiple sclerosis. Congress of the European
Federation of IASP Chapters (EFIC), 2–6 September 2003, Prague
Young RR (1994) Spasticity: a review. Neurology 44:S12–S20
Zajicek J, Fox P, Sanders H, et al (2003) Cannabinoids for treatment of spasticity and
other symptoms related to multiple sclerosis (CAMS study): multicentre randomised
placebo-controlled trial. Lancet 362:1517–1526
Zuardi AW, Guimaraes FS (1997) Cannabidiol as an anxiolytic and antipsychotic. In: Mathre
ML (ed) Cannabis in medical practice: a legal, historical and pharmacological overview
of the therapeutic use of marijuana. McFarland, Jefferson, pp 133–141
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety
and other effects produced by delta-9-THC in normal subjects. Psychopharmacology
(Berl) 76:245–250
Zuardi AW, Rogdrigues JA, Cunha JM (1991) Effects of cannabidiol in animal models
predictive of antipsychotic activity. Psychopharmacology (Berl) 104:260–264
ZuardiAW,CosmeRA,GraeffFG,GuimaraesFS(1993)Effectsofipsapironeandcannabidiol
on human experimental anxiety. J PsychoPharmacol 7:82–88
Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995) Antipsychotic effect of cannabid-
iol. J Clin Psychiatry 56:485–486